SMARCA4/2 loss inhibits chemotherapy-induced apoptosis by restricting IP3R3-mediated Ca2+ flux to mitochondria
SMARCA4/2 loss in ovarian and lung cancers is associated with chemotherapy resistance. Here, the authors show that SMARCA4/2 deficiency in cancer cells reduces the expression of the ER-Ca2+ channel IP3R3 and subsequently calcium transfer to the mitochondria, which inhibits apoptotic cell death.
Guardado en:
Autores principales: | Yibo Xue, Jordan L. Morris, Kangning Yang, Zheng Fu, Xianbing Zhu, Fraser Johnson, Brian Meehan, Leora Witkowski, Amber Yasmeen, Tunde Golenar, Mackenzie Coatham, Geneviève Morin, Anie Monast, Virginie Pilon, Pierre Olivier Fiset, Sungmi Jung, Anne V. Gonzalez, Sophie Camilleri-Broet, Lili Fu, Lynne-Marie Postovit, Jonathan Spicer, Walter H. Gotlieb, Marie-Christine Guiot, Janusz Rak, Morag Park, William Lockwood, William D. Foulkes, Julien Prudent, Sidong Huang |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/bf575d4233b14e5f997658655553d914 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
SMARCA4 loss is synthetic lethal with CDK4/6 inhibition in non-small cell lung cancer
por: Yibo Xue, et al.
Publicado: (2019) -
CDK4/6 inhibitors target SMARCA4-determined cyclin D1 deficiency in hypercalcemic small cell carcinoma of the ovary
por: Yibo Xue, et al.
Publicado: (2019) -
Clinical impact of EZH2 and its antagonist SMARCA4 in ovarian cancer
por: Katharina Leitner, et al.
Publicado: (2020) -
BET inhibitor suppresses migration of human hepatocellular carcinoma by inhibiting SMARCA4
por: Hae In Choi, et al.
Publicado: (2021) -
Chromatin remodeller SMARCA4 recruits topoisomerase 1 and suppresses transcription-associated genomic instability
por: Afzal Husain, et al.
Publicado: (2016)